DexCom, Inc. $DXCM Stock Holdings Trimmed by Marble Harbor Investment Counsel LLC

Marble Harbor Investment Counsel LLC lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 3.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 158,655 shares of the medical device company’s stock after selling 6,341 shares during the quarter. DexCom comprises about 1.5% of Marble Harbor Investment Counsel LLC’s investment portfolio, making the stock its 21st biggest holding. Marble Harbor Investment Counsel LLC’s holdings in DexCom were worth $13,849,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the business. Andra AP fonden bought a new stake in shares of DexCom during the 2nd quarter worth $26,000. Zions Bancorporation National Association UT purchased a new stake in DexCom in the 1st quarter worth approximately $27,000. Anderson Financial Strategies LLC acquired a new stake in DexCom during the first quarter valued at $37,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom in the 2nd quarter valued at approximately $45,000. Finally, Atlantic Union Bankshares Corp acquired a new position in shares of DexCom during the 2nd quarter worth $70,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Trading Up 6.0%

NASDAQ DXCM opened at $58.13 on Wednesday. The stock has a 50 day moving average of $68.51 and a 200-day moving average of $77.51. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The company has a market cap of $22.67 billion, a PE ratio of 40.37, a PEG ratio of 1.43 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter last year, the firm posted $0.45 EPS. The company’s quarterly revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other DexCom news, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction on Monday, November 10th. The stock was sold at an average price of $55.17, for a total transaction of $217,811.16. Following the completion of the sale, the director directly owned 37,994 shares in the company, valued at $2,096,128.98. This represents a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kyle Malady sold 667 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the transaction, the director owned 22,667 shares of the company’s stock, valued at approximately $1,832,853.62. This represents a 2.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 9,331 shares of company stock worth $652,085. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

DXCM has been the subject of a number of analyst reports. Cowen restated a “buy” rating on shares of DexCom in a research note on Friday, October 24th. Robert W. Baird set a $82.00 price target on shares of DexCom in a report on Friday, October 31st. Sanford C. Bernstein restated an “outperform” rating and set a $84.00 target price on shares of DexCom in a research report on Monday, November 3rd. Argus cut their target price on shares of DexCom from $100.00 to $90.00 and set a “buy” rating for the company in a research note on Friday, November 7th. Finally, Truist Financial reissued a “buy” rating and set a $82.00 price objective (down previously from $94.00) on shares of DexCom in a report on Monday, November 3rd. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus price target of $87.62.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.